What is the primary use for Raloxifene (Evista)?

Raloxifene, marketed under the name Evista, is primarily used for osteoporosis prevention. It is a selective estrogen receptor modulator (SERM) that mimics estrogen's beneficial effects on bone density without some of the risks associated with estrogen therapy. By binding to estrogen receptors in bone tissue, Raloxifene helps to maintain or improve bone density, thus reducing the risk of fractures in postmenopausal women, who are particularly susceptible to osteoporosis due to decreased estrogen levels.

While Raloxifene has shown some efficacy in reducing the risk of certain types of breast cancer, its main approval and use focus is on the prevention and treatment of osteoporosis rather than as a primary cancer treatment. It is also not indicated for hormone replacement therapy, which generally involves administering estrogen or combined hormone therapies to manage menopause symptoms. Lastly, Raloxifene is not used as a contraceptive method, as it does not prevent ovulation or affect fertility.